Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F. Martino M, et al. Among authors: musolino c. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):148-54. doi: 10.1016/j.clml.2013.11.009. Epub 2013 Nov 22. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24417912
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M, Alati C, Vincelli ID, Piro E, Penna G, Musolino C, Ronco F, Molica S, Morabito F. Martino M, et al. Among authors: musolino c. Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15. Cytotherapy. 2015. PMID: 26188967
High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P. Martino M, et al. Among authors: musolino c. Am J Hematol. 2006 Dec;81(12):973-8. doi: 10.1002/ajh.20677. Am J Hematol. 2006. PMID: 16888786 Free article. Clinical Trial.
Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Martino M, Morabito F, Console G, Irrera G, Messina G, Pucci G, Nardi M, Nobile F, Molica S, Cicero G, Palazzo S, Peta A, Musolino C, Iacopino P. Martino M, et al. Among authors: musolino c. Tumori. 2003 Jul-Aug;89(4):385-90. doi: 10.1177/030089160308900407. Tumori. 2003. PMID: 14606640
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. Morabito F, et al. Among authors: musolino c. Blood. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27. Blood. 2011. PMID: 21951682 Free article. Clinical Trial.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders. Mauro FR, et al. Among authors: musolino c. Leuk Res. 2014 Feb;38(2):198-203. doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19. Leuk Res. 2014. PMID: 24314589 Clinical Trial.
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M, Cutrona G, Mosca L, Matis S, Fabris S, Lionetti M, Ilariucci F, Zupo S, Musolino C, Levato L, Molica S, Di Raimondo F, Vincelli I, Di Rienzo N, Pesce EA, Angrilli F, Federico M, Neri A, Ferrarini M, Morabito F. Gentile M, et al. Among authors: musolino c. Am J Hematol. 2014 Jul;89(7):743-50. doi: 10.1002/ajh.23729. Epub 2014 Apr 18. Am J Hematol. 2014. PMID: 24711230 Free article.
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F, Cutrona G, Mosca L, D'Anca M, Matis S, Gentile M, Vigna E, Colombo M, Recchia AG, Bossio S, De Stefano L, Maura F, Manzoni M, Ilariucci F, Consoli U, Vincelli I, Musolino C, Cortelezzi A, Molica S, Ferrarini M, Neri A. Morabito F, et al. Among authors: musolino c. Leuk Res. 2015 Aug;39(8):840-5. doi: 10.1016/j.leukres.2015.05.005. Epub 2015 May 19. Leuk Res. 2015. PMID: 26038121 Clinical Trial.
Vaccination of multiple myeloma: Current strategies and future prospects.
Allegra A, Penna G, Innao V, Greve B, Maisano V, Russo S, Musolino C. Allegra A, et al. Among authors: musolino c. Crit Rev Oncol Hematol. 2015 Nov;96(2):339-54. doi: 10.1016/j.critrevonc.2015.06.003. Epub 2015 Jun 18. Crit Rev Oncol Hematol. 2015. PMID: 26123319 Review.
277 results